OLP is a relatively common chronic inflammatory autoimmune disease. OSCC can be preceded by potentially malignant lesions such as OLP (
4). Although the WHO classifies OLP as a potentially malignant oral lesion, there is considerable controversy regarding the malignant potential of this lesion. This controversy is due to a wide range of malignant transformation rates (0% - 12.5%) in OLP patients as well as different clinical criteria used for diagnosis of this lesion. Nevertheless, most studies demonstrated that OLP patients develop oral cancer at an increased rate (approximately 10 times higher risk) when compared to the general population (
13,
14). A meta-analysis study also reported malignant transformation of OLP six years after the initial diagnosis with the mean rate of 0.27% per year (
14).
Lodi et al. reported that the presence of epithelial dysplasia in an OLP lesion may correspond to two types of conditions: lesions with clinical features of OLP but with dysplasia at histological level and lesions with lichenoid histopathological features (particularly band-like inflammatory infiltration) but without the classic clinical features of OLP (e.g. with unilateral distribution or absence of reticular lesions). The former may represent an early phase of OLP malignant transformation, whereas the latter may correspond to one of the various clinical conditions (
15). In addition, it is probably well accepted that the final diagnosis of OLP cannot be made on histopathological features alone and that often clinical and histopathological evaluation is required (
16). Therefore, in order to achieve appropriate results in the present study, cases with fulfillment both clinical and histopathological features of OLP were selected. Concerning the clinical form of OLP, numerous authors have found that atrophic-erosive forms predisposed to cancer development (
15).
The role of CSCs in epithelial dysplasia, tumor development, growth, and metastasis has been approved and investigated by various studies. Malignant transformation of dysplastic epithelium is reported to be 3% to 36% (
1). Therefore, evaluation of CSC markers, including CD44, seems to be necessary for dysplastic and premalignant lesions such as OLP.
It has been shown that chronic inflammation may induce some epithelial malignancies. The relation between chronic esophagitis and esophageal adenocarcinoma as well as intestinal cancer and chronic inflammatory bowel disease has been reported (
9).
It should be noted that inflammation itself, the basic pathological feature of OLP, can elicit histological features similar to mild dysplasia (
15). Moreover, particularly in mild cases of dysplasia chronic inflammatory host response to the atypical cells of epithelial dysplasia can appear histopathologically similar to OLP (
3). Therefore, although most of our reporting system included a diagnostic category of mild and moderate dysplastic OLP, we evaluated only moderate dysplastic OLP in our study.
CD44, as a cell adhesion molecule is expressed on epithelial cells and also leukocytes. This marker along with its ligand, hyaluronan (HA), is involved in various inflammatory diseases, including OLP. Investigating the role and functional mechanism of CD44 can serve as a therapeutic goal in chronic inflammatory diseases (
10).
In the present study, CD44 expression as a CSC marker was evaluated in dysplastic and non-dysplastic OLP. Furthermore, the expression of this marker in sub-epithelial lymphocytes of OLP as a chronic inflammatory disease was investigated. Some other studies (
17) evaluated definitely epithelial dysplasia, whereas in the current study, after confirming the OLP diagnosis, the dysplastic changes in OLP lesions were evaluated. Therefore, to the best of our knowledge, CD44 expression in dysplastic OLP was evaluated for the first time in this study.
According to our results, higher expression of CD44 was reported in dysplastic lesions which shows the role of this marker in the carcinogenesis process as a CSC marker. Consistent with the findings of the present study, Kaya et al. also showed a high CD44 expression in epithelial keratinocytes of OLP (
18).
Santarelli et al. reported that CD44 and osteopontin expression in epithelium of OLP patients were significantly higher than the control group and they concluded that these markers could play a role in the pathogenesis of OLP (
19). Siponen et al. also demonstrated a higher expression of hyaluronan, CD44, HASI-3, and HYALI-2 in the epithelium of OLP patients compared to the control group (
20).
Since CD44 is expressed on both lymphocytes and parenchymal cells, in addition to the role of this marker in the carcinogenesis process, its role in autoimmune diseases has also been taken into account in recent years (
10).
One of the early events in inflammatory responses is the recruitment of inflammatory cells that are mediated by cell-adhesion molecules such as CD44 and the production of chemical adsorbents. Evidence showed that CD44 plays a major role in various inflammatory diseases and according to the previous studies the application of the Anti-CD44 antibody can control inflammatory bowel disease and skin encephalomyelitis (
10).
In the current study, the expression of CD44 in OLP samples demonstrates its role in the recruitment of T lymphocytes in the pathogenesis of this lesion. In the study by Liu et al. most of the T cells infiltrated in the OLP lamina properia showed high CD44 immunoreactivity (
21).
Mignogna et al. also evaluated the role of inflammation in the malignant transformation of OLP. According to their study, sub-epithelial infiltration of inflammatory cells and cytokines network can be associated with the tumorigenesis and malignant transformation of OLP (
9).
Yasuda et al. also reviewed the relevance of CD44 with inflammation and malignancy. They stated that CD44 as a major receptor for hyaluronan (an essential component of the extracellular matrix) has an important role in the inflammation process and potential for tumor formation. Therefore, a special focus should be placed on CD44-mediated signaling pathways in therapeutic approaches (
22).
Similar to our results, Kaya et al. investigated CD44 isoforms including (CD44s and CD44V3-10) in OLP and observed CD44s immunoexpression in sub-epithelial lymphocytes and epithelial keratinocytes. Epithelial immunoreactivity of CD44v isoforms was decreased or absent. They concluded that the expression of CD44 isoforms in OLP is different from cutaneous LP which revealed that CD44 may play a role in the formation of LP in different locations (
18).
In the present study, although there was no significant difference for expression of CD44 in sub-epithelial lymphocytes between dysplastic and non-dysplastic lesions, a higher immunoexpression in dysplastic lesions was observed, that indicates the role of this marker in the process of inflammation as well as malignant transformation. As previously noted, epithelial immunoreactivity was significantly higher in dysplastic lesions, which possibly shows the more important role of this marker in the carcinogenesis process.
5.1. Conclusions
Immunoexpression of CD44 in the epithelium and sub-epithelial lymphocytes of OLP indicates the probable role of this marker in the pathogenesis of this lesion as an inflammatory chronic autoimmune disease.
Significant higher expression of CD44 as a CSC marker in the epithelium of dysplastic OLP may show the role of this marker in malignant transformation and carcinogenesis process of this premalignant lesion. Higher immunoreactivity in sub-epithelial lymphocytes of dysplastic type indicates a probable role of chronic inflammation in the malignant potential of OLP similar to some other chronic inflammatory diseases.